RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount
RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data. Click here to read why RNXT stock presents ...
Clot Management Devices Market to Reach $4.3 billion, Globally, by 2035 at 6.2% CAGR ...
Rise in prevalence of thromboembolic disorders, surge in trend toward minimally invasive surgeries, and rise in adoption of strategies by the key players drive the growth of the clot management ...